Navigation Links
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
Date:8/3/2009

ion and enables the formulation of an aqueous suspension for once-monthly intramuscular administration. INVEGA(R) SUSTENNA(TM) is manufactured by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, in the U.S.

About J&JPRD

INVEGA(R) SUSTENNA(TM) was developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), a member of the Johnson & Johnson family of companies, the world's most broadly-based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States, and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine, and Oncology, to address unmet medical needs worldwide. More information can be found at http://www.jnjpharmarnd.com.

About Janssen

Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, is based in Titusville, N.J., and is the only large pharmaceutical company in the U.S. dedicated solely to mental health. It currently markets prescription medications for the treatment of schizophrenia, bipolar mania, schizoaffective disorder, and the treatment of symptoms associated with autistic disorders. Ortho-McNeil-Janssen Pharmaceuticals, Inc is a member of the Johnson & Johnson family of companies. For more information about Janssen, visit http://www.janssen.com/.

About NanoCrystal((R)) Technology and Elan Drug Technologies

INVEGA(R) SUSTENNA(TM) utilizes the NanoCrystal((R)) Technology, which is a proprietary technology developed by Elan Drug Technologies through Elan Pharma International Limited and other Elan affiliates. NanoCrystal((R)) Technology is a registered trademark of Elan Pharma International Limited, Ire
'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skins Natural Moisture
2. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
3. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
4. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
5. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
6. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
7. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
8. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
9. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
10. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
11. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research Report ... "2014 Deep Research Report on Global and China ... database. Photo - http://photos.prnewswire.com/prnh/20140731/132164 ... on Global and China Potassium Nitrate  Industry" is ... China and Global Potassium Nitrate ...
(Date:7/31/2014)... , July 31, 2014  According to data released ... the 2015 average monthly Medicare Part D premium is ... lower than was originally projected, the Pharmaceutical Care Management ... program continues to be a bright spot in American ... in each region and using cutting edge, cost-saving tools ...
(Date:7/31/2014)... Surgical Company (NASDAQ: STAA ) a leading ... systems for the eye today reported revenue for the ... a 10% increase over $18.2 million reported for the ... revenues grew 11% during the second quarter of 2014 ... of foreign currency exchange reduced sales by $0.1 million ...
Breaking Medicine Technology:Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... (NYSE-Amex: NBS ) today announced that it intends to ... an underwritten public offering. All of the shares and warrants in ... to market conditions, and there can be no assurance as to ... the actual size or terms of the offering. The shares will ...
... Ohio, July 18, 2011 BioTech Medical, Inc. announces the ... Dental Chair Pad and Head Cushion to its ... "There isn,t a day that goes by that our ... Tippey, Director of Medical Operations for BioTech Medical, Inc.  "We ...
Cached Medicine Technology:NeoStem Announces Proposed Public Offering of Common Stock 2NeoStem Announces Proposed Public Offering of Common Stock 3
(Date:8/1/2014)... Everett, WA (PRWEB) August 01, 2014 ... a problem throughout your entire home.“ In a newly ... Space or Attic Insulation Needs To Be Replaced ,” ... has deteriorated, become damp, or been infested by critters. ... space cleaning quote from Clean Crawls - http://www.cleancrawl.com/contact ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The Multiple System ... to serving patients, caregivers and families affected by the neurological ... Kramer Sutton of La Coste, TX to its Board of ... of 39 years, Eric Sutton. He was diagnosed officially with ... at home with his family. Like many others with this ...
(Date:8/1/2014)... 01, 2014 Narrow networks that ... and employers effective options to trim pharmacy costs ... that they can enhance formulary compliance and achieve ... report that nearly all PBMs now include a ... proposals. The Aug. 12 webinar from Atlantic ...
(Date:8/1/2014)... 01, 2014 Millions of women suffer ... legs and in some cases the arms, causing an ... about 17 million women in the U.S. alone are ... with the pain, embarrassment and discomfort caused by lipedema, ... physicians are unaware that this is a disease,” says Dr. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Get the ... partnership with PitchBook presents the 3Q 2014 Private Equity ... private equity investment, exits and fundraising activity in the ... to help plan for private equity endeavors for the ... form to download it now. , About Merrill DataSite ...
Breaking Medicine News(10 mins):Health News:5 Signs That Insulation Should Be Replaced Detailed in a Newly Released Article By Clean Crawls 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 2Health News:Sharon Kramer Sutton, 30 Year Veteran of Rare Disease Advocacy, Appointed to Multiple System Atrophy Coalition Board of Directors 3Health News:Atlantic Information Services Webinar to Offer Health Plan, Employer Strategies for Implementing Narrow Pharma Networks 2Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2
... Nov. 21 Inverness Medical,Innovations, Inc. (Amex: IMA ... offering on Tuesday. The Company sold a total,of 13,634,302 ... of $61.49,per share. The total number of shares sold ... upon their exercise of their,over-allotment option in full. Certain ...
... The precise tailoring of tumor target treatment for patients ... to only administer treatments that have a high probability ... on imaging technologies, which are used to detect tumors ... guide therapy or surgery. , Vascular endothelial growth ...
... arterial vascular disease is widespread and often deadly among ... and treat it, according to a new report by ... Medical Center and Weill Cornell Medical College campuses of ... the fact that for years, cardiovascular research has focused ...
... Portable M5 Diagnostic Imaging Systems, SHENZHEN, China, ... MR ), a leading developer, manufacturer,and marketer ... growing,international presence, today announced that it will attend ... in Chicago,Illinois at the McCormick Place from November ...
... 21 Genomic Health,Inc. (Nasdaq: GHDX ) ... and Chief Executive Officer, will present at the ... on November 28, 2007 at 1:00,p.m. Eastern Time., ... webcast of the,presentation, visit the Investor Relations section ...
... Eclipsys Corporation(R),(Nasdaq: ECLP ), The Outcomes ... Merrill Lynch Health Services Investor Conference,taking place next ... http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO ), Eclipsys executives will present ... a.m. Eastern time. Interested parties are invited to,listen ...
Cached Medicine News:Health News:Inverness Medical Innovations Announces Closing of Public Offering 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 3Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 4Health News:Mindray to Attend 2007 RSNA Conference in Chicago 2Health News:Mindray to Attend 2007 RSNA Conference in Chicago 3Health News:Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 3
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: